Clinical trial · Observational
Prognostic Biomarkers of Pancreatic Cancer Based on Proteomics Techniques
NCT05088161CI-TRIAL-00054600unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, we will use high-throughput proteomics techniques to search for biomarkers of post-operative prognosis of pancreatic cancer in samples of patients who have been diagnosed with pancreatic cancer through bioinformatics analysis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Patients | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Differentially expressed proteins in tumor and paracancer tissues
- timeFrame
- 180 Days
- description
- Two dimensional gel electrophoresis, mass spectrometry and other techniques were used to separate and compare pancreatic cancer tissues and normal adjacent tissues to search for differentially expressed proteins.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients of Chinese nationality, age and gender are not limited. * Pathologically confirmed pancreatic cancer patients. * Pathological specimens were archived tumor tissue samples after a diagnosis of pancreatic cancer. * Clinical diagnostic information was complete three months before sampling. Exclusion Criteria: * Patients with a second primary tumor.
References
Publications (0)
Data not yet available
No reference posted for this study.